NNZ-2566: Phase II data

Top-line data from a double-blind, placebo-controlled, U.S. Phase II trial in 53 female Rett syndrome patients ages 16-45 showed that twice-daily 35 and 70 mg/kg doses of oral NNZ-2566 for up to 28 da...